

xDRIVE for Florida-based Cancer Patients

NCT07167381

Status	RECRUITING
Phase	Not Applicable
Sponsor	First Ascent Biomedical Inc.
Enrollment	210 participants

Plain Language Summary

This study (xDRIVE) uses tumor genetic testing and AI to help match Florida cancer patients with the clinical trial or treatment most likely to work for their specific cancer. It is a precision oncology program — rather than a single treatment, it uses your tumor's DNA to personalize recommendations.

****You may be eligible if...****

- You have cancer that has come back or stopped responding to treatment (recurrent or refractory)
- You are any age (children and adults are both eligible)
- You have received at least one prior standard treatment
- You are healthy enough to undergo cancer therapy (ECOG 0–2 for adults)
- You are scheduled for or have recently had a tumor biopsy, removal, or resection
- You are willing to provide a blood sample or cheek swab

****You may NOT be eligible if...****

- You are unable to provide prior treatment information
- You are not able to provide a tissue sample for DNA analysis
- You are not in sufficient health to receive treatment

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (7)

- Patients with recurrent/refractory cancer patients up to age 18 (willing to sign assent if ages 7 - 17 years)
 - OR- Patients with recurrent/refractory cancer e18 years of age.
 - Patients who have received at least one prior line of standard of care therapy.
 - Patients able to provide treatment and outcome information from previous line(s) of therapy.
 - Patients with sufficient health status to undergo cancer therapy, e.g., Eastern Cooperative Group (ECOG) performance status of 0, 1, or 2 for adult patients.
- ... and 2 more (see full listing online)

Exclusion (2)

- Patients who do not have malignant tissue available and accessible, patients where the amount of excised malignant tissue is insufficient material for ex vivo drug testing and/or genetic profiling, defined as <0.3g for resections or core/fine-needle biopsies not containing malignant tissue by pathology review, or insufficient malignant tissue in peripheral blood or bone marrow aspirate samples.
- Patients with insufficient health indicators to undergo therapeutic intervention.

Locations (2 total)

First Ascent Biomedical, Miami, Florida, United States

<http://FloridaInternationalUniversity.com>, Miami, Florida, United States

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.